Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Annuity Payment Model For Cures May Get Test Drive In Massachusetts

Executive Summary

First-ever implementation of often-discussed reimbursement approach for high-cost drugs would involve group of commercial payers to address “portability” issue and may start with Novartis’ Zolgensma.

You may also be interested in...



How Should Medicaid Pay For Cures? Sen. Grassley Likes Annuity Model

Finance Committee chairman wants a provision allowing Medicaid to make installment payments for high-cost curative treatments in drug pricing legislation. But Democrats worry such a model might encourage high prices.

Paying For Gene Therapy: Medicaid Will Be ‘Canary In Coal Mine’

Harvard Pilgrim's Michael Sherman and Cigna's Steve Miller advise gene therapy developers to consider the burden of high cost treatments on Medicaid programs when setting list prices.

Taking PBMs To The “OR”: Orphan Reinsurance Model Could Be New “Middleman” Role

MIT Center for Biomedical Innovation is proposing creation of Orphan Reinsurance Benefit Managers as one mechanism to help finance curative cellular and gene therapies. The idea may or may not prove viable – but it is a reminder that “middlemen” aren’t likely going away even if rebates do.  

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS124767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel